Dr. Ashton has a decade of experience in biofluid analysis and assay development for Alzheimer’s disease and related disorder which ranges from discovery mass spectrometry methods to ultra-sensitive immunoassays development. Recently, this has seen the success of assays specific for phosphorylated tau and neurofilament light, which being evaluated for clinical routine across Europe and inclusion criterion for clinical trials targeting dementia. Dr. Ashton was the 2021 recipient for the Queen Silvia prize for Alzheimer’s research in Sweden and published >100 original research articles in fluid biomarker for neurogenerative diseases.
Ultrasensitive Biomarkers for Amyloid Burden
Alzheimer’s disease is one of our nation’s most significant threats, with devastating impacts on patients and their families. This session will explore a new approach called neurodiagnostic therapies, a methodology fundamentally enabled by ultrasensitive biomarker measurements that allow visibility to neurological disease in individuals before they are symptomatic. This allows treatment to be administered at a more optimal stage, to improve therapeutic effectiveness and by extension, patient outcomes.
During this presentation, attendees will learn how this new approach can provide early treatment to ultimately accelerate disease detection and improve outcomes, in addition to creating viable and credible evidence for the healthcare system to adopt it with coverage to facilitate frictionless access.